A new analysis has challenged an earlier assessment of the severity and prevalence of withdrawal symptoms following antidepressant use, sparking a renewed debate over long-term mental health treatment strategies.
The review, published July 9 in JAMA Psychiatry, included more than 17,000 patients across 50 studies and found that symptoms such as dizziness, nausea and vertigo were all more common in patients who stopped taking an antidepressant compared with those who had been on a placebo, with symptoms generally remaining below clinically significant levels.
The findings contrast with a 2019 analysis that found 56% of patients experienced withdrawal symptoms, nearly half which were described as severe, The New York Times reported July 9.
The earlier study prompted changes to psychiatric guidelines in the United Kingdom and ignited concerns among patients and providers. Critics of the 2019 findings — including Sameer Jauhar, MD, a senior lecturer at the Imperial College of London and a co-author of the study — argued that the earlier research lacked methodological rigor and may have overstated risks.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
